Avastin vs. Lucentis…and the Winner is!
December 12, 2009
Finally, a small study reveals………..no difference between Avastin® (bevacizumab) or Lucentis® (ranibizumab) when used to treat age related macular degeneration.
Twenty patients were randomized to either Avastin or Lucentis treatment for wet ARMD. The study lasted 6 months. All patients received 3 injections spaced one month apart. Additional injections were delivered based upon OCT changes.
In both groups, there was an improvement in vision and a decrease (as measured with OCT) in macular thickness at 6 months. While the bevacizumab group required, on average, slightly more injections than the ranibizumab group, the number was not statistically significant.
What Does This Mean? This study involved on 20 patients, hardly enough to change practice patterns, but does carry some significance. It does validate a trend that we have seen in our neck of the woods, in that, most retina specialists use Avastin/bevacizumab as their first line of treatment.
I know, we’ll wait for the hard data.
The full article; AJO. 2009;148(6):875-882.
Randall V. Wong, M.D.
Retinal Specialist in Fairfax Virginia
You might also enjoy...
- Pharmacokinetics of Lucentis and Avastin, Better Outcomes?
- Avastin Compares to Lucentis
- Study Indicates Avastin (bevacizumab) May Work for Diabetic Macular Edema
- Is Lucentis (ranibizumab) Effective in Treating CRVO?
- CATT Study Finds No Difference Between Avastin and Lucentis in Stopping Progression of Wet Macular Degeneration
Jump down to form below to submit your own comments